- Home
- GDTC vs PYPD Comparison
GDTC vs PYPD Comparison
Compare GDTC & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- PYPD
- Stock Information
- Founded
- GDTC 2018
- PYPD 2008
- Country
- GDTC Singapore
- PYPD Israel
- Employees
- GDTC N/A
- PYPD N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- GDTC Health Care
- PYPD Health Care
- Exchange
- GDTC Nasdaq
- PYPD Nasdaq
- Market Cap
- GDTC 29.4M
- PYPD 30.1M
- IPO Year
- GDTC 2023
- PYPD 2020
- Fundamental
- Price
- GDTC $2.23
- PYPD $2.71
- Analyst Decision
- GDTC Buy
- PYPD Strong Buy
- Analyst Count
- GDTC 1
- PYPD 2
- Target Price
- GDTC $5.00
- PYPD $10.50
- AVG Volume (30 Days)
- GDTC 15.9K
- PYPD 12.4K
- Earning Date
- GDTC 01-01-0001
- PYPD 05-07-2025
- Dividend Yield
- GDTC N/A
- PYPD N/A
- EPS Growth
- GDTC N/A
- PYPD N/A
- EPS
- GDTC N/A
- PYPD N/A
- Revenue
- GDTC $330,254.00
- PYPD N/A
- Revenue This Year
- GDTC $14.71
- PYPD N/A
- Revenue Next Year
- GDTC N/A
- PYPD N/A
- P/E Ratio
- GDTC N/A
- PYPD N/A
- Revenue Growth
- GDTC N/A
- PYPD N/A
- 52 Week Low
- GDTC $1.20
- PYPD $2.37
- 52 Week High
- GDTC $4.05
- PYPD $5.09
- Technical
- Relative Strength Index (RSI)
- GDTC 34.89
- PYPD 42.57
- Support Level
- GDTC $1.98
- PYPD $2.66
- Resistance Level
- GDTC $2.56
- PYPD $2.75
- Average True Range (ATR)
- GDTC 0.18
- PYPD 0.12
- MACD
- GDTC -0.04
- PYPD -0.01
- Stochastic Oscillator
- GDTC 31.25
- PYPD 11.48
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.